Ventyx Biosciences — Technical Presentation (October 2025)
30 slides from Ventyx Biosciences's technical presentation, Oct 22, 2025
Slide 1: Phase 2 Trial of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors
Exhibit 99.2 Phase 2 Trial of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors Topline Results October 22, 2025
Slide 2: Forward Looking Statements
Forward Looking Statements Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Su
Slide 3: Today's Presenters
Today’s Presenters Ventyx Management Team Guest Speakers and KOLs Raju Mohan, PhD Mark Forman, MD, PhD Matthew Moore Peter Libby, MD Antonio Abbate, MD, PhD CHIEF EXECUTIVE OFFICER, CHIEF MEDICAL OFFICER CHIEF OPERATING OFFICER MASS GENERAL BRIGHAM UNIVERSITY OF VIRGINIA, FOUNDER HEART & VASCULAR IN
Slide 4: VTX3232 Phase 2 Trial Top-Line Results and Key Takeaways
VTX3232 Phase 2 Trial Top-Line Results and Key Takeaways • Rapid and sustained reductions in hsCRP with VTX3232 vs. placebo • Statistically significant decrease in hsCRP of up to 80% within first week of treatment • Majority of participants achieved hsCRP levels of <2 mg/L at Week 12, a critical thr
Slide 5: The NLRP3 Inflammasome is a Central Instigator of Innate Immune Response to Tissue Damage
The NLRP3 Inflammasome is a Central Instigator of Innate Immune Response to Tissue Damage Strong mechanistic rationale through modulation of NLRP3 / IL-1β / IL-6 / CRP signaling Active NLRP3 Inflammasome Mechanistic Rationale § NLRP3 inflammasome dysregulation is linked to diverse metabolic, cardiov
Slide 6: Mark Forman, MD, PhD, Chief Medical Officer
Mark Forman, MD, PhD Chief Medical Officer
Slide 7: Phase 2 Trial of VTX3232 in Participants with Obesity and CV Risk Factors
1 Phase 2 Trial of VTX3232 in Participants with Obesity and CV Risk Factors Randomization Double-Blind 12-Week Treatment Follow-Up Placebo QD VTX3232 30 mg QD 1:1:1:1 N=176 * 2 Placebo QD + Semaglutide QW * * 2 VTX3232 30 mg QD + Semaglutide QW * Key Eligibility Criteria Endpoints Analysis Populatio
Slide 8: Participant Disposition
Participant Disposition Randomized and Treated (N=175) P Plla ac ce eb bo o Q QD D V VT TX X3 32 23 32 2 3 30 0 m mg g Q QD D P Plla ac ce eb bo o Q QD D V VT TX X3 32 23 32 2 3 30 0 m mg g Q QD D + + W We ee ek klly y S Se em ma ag gllu ut tiid de e + + W We ee ek klly y S Se em ma ag gllu ut tiid
Slide 9: Baseline Characteristics
Baseline Characteristics Consistent with trial population and generally balanced across treatment arms Placebo QD VTX3232 30 mg QD Placebo QD VTX3232 QD 30 mg Total Baseline Characteristic + Semaglutide QW + Semaglutide QW (N=43) (N=44) (N=175) (N=43) (N=45) Age, years, mean (SD) 47.0 (13.5) 45.9 (1
Slide 10: VTX3232 was Safe and Well-Tolerated in the Phase 2 Study
VTX3232 was Safe and Well-Tolerated in the Phase 2 Study Most TEAEs were mild to moderate in severity; no serious or opportunistic infections* No clinically meaningful differences in the two analysis populations Placebo QD VTX3232 30 mg QD Placebo QD VTX3232 30 mg QD Treatment Emergent Adverse Event
Slide 11: VTX3232 Induced Rapid and Durable Reductions in hsCRP
VTX3232 Induced Rapid and Durable Reductions in hsCRP ~80% Decrease from Baseline in hsCRP after 1st Week Majority of participants achieved an hsCRP of <2 mg/L at Week 12 *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared to Placebo; Data shown are Median (IQR); p-value derived from Wilcoxon Rank
Slide 12: VTX3232 Induced Rapid and Durable Reductions in hsCRP
VTX3232 Induced Rapid and Durable Reductions in hsCRP ~80% Decrease in hsCRP after 1 Week of Treatment - Sustained through Week 12 *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared to Placebo; ###p<0.001, ####p<0.0001 compared to Placebo + Semaglutide 1 Modified analysis set (“MAS”) includes disc
Slide 13: VTX3232 Demonstrated Deep Reductions in hsCRP at Week 12
VTX3232 Demonstrated Deep Reductions in hsCRP at Week 12 *p<0.05, ****p<0.0001 compared to Placebo; ###p<0.001, ####p<0.0001 compared to Placebo + Semaglutide 1 Modified analysis set (“MAS”) includes discontinuations; excludes participants with no detectable VTX3232 blood levels at week 12; Data sho
Slide 14: Majority of Participants on VTX3232 had hsCRP of <2 mg/L at Week 12
Majority of Participants on VTX3232 had hsCRP of <2 mg/L at Week 12 2 Patients with hsCRP ≥2 mg/L are at greater risk of future cardiovascular events 3 ACC scientific statement recommends targeting inflammation in primary and secondary CV prevention 1 *p<0.05, ****p<0.0001 compared to Placebo; ####p
Slide 15: Levels of IL-6 at Week 12 Reduced Below Threshold for CV risk
1 Levels of IL-6 at Week 12 Reduced Below Threshold for CV risk 3 Full Analysis Set Modified Analysis Set Low CV Risk 1 Threshold Full Set Modified Set • VTX3232 reduces IL-6 levels below CV risk threshold Baseline Week 12 Baseline Week 12 while maintaining immune homeostasis Treatment IL-6 (ng/L) I
Slide 16: VTX3232 Reduced Lipoprotein(a), Fibrinogen, and ESR
VTX3232 Reduced Lipoprotein(a), Fibrinogen, and ESR Statistically significant reduction in inflammatory biomarkers of NLRP3 activity *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared to Placebo; # p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001 compared to Placebo + Semaglutide Full analysis set is sh
Slide 17: No Clinically Meaningful Change in Lipid Parameters with VTX3232
No Clinically Meaningful Change in Lipid Parameters with VTX3232 Consistent with the Safety Profile of VTX3232 *p<0.05, **p<0.01, ***p<0.001 compared to Placebo; # p<0.05 compared to Placebo + Semaglutide Data shown are Median (IQR); p-value derived from Wilcoxon Rank Sum Test; For LDLc, Placebo n =
Slide 18: VTX3232 Did Not Decrease Body Weight
VTX3232 Did Not Decrease Body Weight 1 Weight Loss Associated with Semaglutide Consistent with Published 12-week Data *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared to Placebo; Dose escalation for semaglutide; 0.25 mg semaglutide weeks 0 - 3, 0.5 mg semaglutide weeks 4 – 7; 1 mg semaglutide we
Slide 19: Change in Liver Fat and Inflammation in Participants With ≥5% Baseline Liver Fat
Change in Liver Fat and Inflammation in Participants With ≥ 5% Baseline Liver Fat VTX3232 Decreased Liver Inflammation at Week 12; Greater Effects with Semaglutide *p<0.05, **p<0.01, ***p<0.001 compared to Placebo Participants represented had >5% liver fat at baseline; cT1, corrected T1; Data shown
Slide 20: VTX3232: Targeting Inflammation in CV Disease with Optimal Benefit-Risk Profile
VTX3232: Targeting Inflammation in CV Disease with Optimal Benefit-Risk Profile • Rapid and sustained reductions in hsCRP vs. placebo § Decrease in hsCRP of ~80% within first week of treatment § Achieves target levels of hsCRP reduction in ~70% of participants • Comprehensive inhibition of NLRP3 pat
Slide 21: Raju Mohan, PhD, Chief Executive Officer
Raju Mohan, PhD Chief Executive Officer
Slide 22: Vast Market Opportunity for Residual Inflammation Reduction in CVD
Vast Market Opportunity for Residual Inflammation Reduction in CVD Tens of millions of CV patients globally with residual inflammatory risk Estimated US CV populations with residual inflammatory risk (hsCRP > 2mg/L) Sources: Gregg C. et. al. Heart Failure Epidemiology and Outcomes Statistics. JCF 20
Slide 23: Our Phase 2 Data Support VTX3232's Best-in-Class Potential for the Treatment of Cardiovascular Disease
Our Phase 2 Data Support VTX3232’s Best-in-Class Potential for the Treatment of Cardiovascular Disease VTX3232 Significant Anti-Inflammatory Effects Vast Cardiovascular Opportunity Potential First-Line Therapy • Inflammation has emerged as a pivotal • Reductions in hsCRP of up to 80% • Oral, once-da
Slide 24: Expert Perspective
¢Aventyx ~ BIOSCIENCES Expert Perspective
Slide 25: Expert Perspectives on Inflammation and Cardiovascular Risk
Expert Perspectives on Inflammation and Cardiovascular Risk Peter Libby, MD Antonio Abbate, MD, PhD Ruth C. Heede Professor of Cardiology, Cardiovascular Specialist at Mass General Brigham Heart & Vascular Institute University of Virginia, School of Medicine Immediate Past President of the Internati
Slide 26: An Academic Clinical Cardiologist's View of the Data
An Academic Clinical Cardiologist’s View of the Data Antonio Abbate, MD, PhD Ruth C. Heed Professor of Cardiology Berne ee scular eee Cent Department of Me cine, “Oviston of Cardiovascular Medici University of Virginia. @AbbateAntonio a7 ‘CARDIOVASCULAR ‘MEDICINE WV A wes
Slide 27: From C-Reactive Protein to Interleukin-6 to Interleukin-1
From C-Reactive Protein to Interleukin-6 to Interleukin-1 Moving Upstream To Identify Novel Targets for Atheroprotection Paul M Ridker Circ Res 2016 Coronary Heart Disease = 25 —| 220% a - _ yer ges ‘ 2» |4 + = + Hossein 5 amg vec ntriation = i echt cioe Pe) ee ee) reno a [0 rr hsCRP concentration (
Slide 28: Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement
ion and Car Disease: 2025 ACC Scientific Statement ‘A Report of the American College of Cardiology George A. Mensah, MD, FACC, Chair Natalie Amold, MD th D. Prabhu, MD, FACC Paul M Ridker, MD, MPH, FACC MD, PuD, FACC The time for taking action has now arrived , wes + Measure hsCRP in everyone ° ° As
Slide 29: From C-Reactive Protein to Interleukin-6 to Interleukin-1 VTX3232: Oral NLRP3 Inflammasome Inhibitor
m C-Reactive Protein to Interleukin-6 to Interleukin-1 VTX3232: Oral NLRP3 Fro Moving Upstream To Identify Novel Targets for Atheroprotectio Paul M Rider ire Res 2016 Inflammasome Inhibitor bi 100- Be. - i : « ae “ 2» ol ar? ? 7 ° Pcebo (e) + Semapaie (N43) am via iong 4s) “ge viazio20m9 = Seng 5) C
Slide 30: Question & Answer
¢Aventyx ~ BIOSCIENCES Question & Answer
Ventyx Biosciences — Technical Presentation (October 2025) on 6ix